Albert Seymour, Ph.D

Dr. Albert Seymour is the Chief Scientific Officer at Homology Medicines, Inc.  He received his Bachelor’s degree in Biology from the University of Delaware, followed by his Master’s in Molecular Genetics from The Johns Hopkins University School of Medicine.  In 1997, Dr. Seymour completed his PhD in Human Genetics at the University of Pittsburgh.  He has since spent more than 20 years combining his talents in pharmaceutical R&D with human genetics, resulting in the delivery of several therapeutic programs into development.  Before joining Homology, Dr. Seymour was the Senior Vice President and Global Head of Research and Nonclinical Development at Shire.  Prior to this role, he also served as the VP and Head of Drug Discovery and Translational Research at Shire, where he doubled the rare disease discovery portfolio in three years.  Dr. Seymour is also a member of the Board of Directors of Ensoma.

In his six years at Homology, Dr. Seymour has helped to advance three programs from scientific concept to clinical development including the world’s first gene therapy clinical trial for PKU.  He has also helped to establish a pipeline of genetic medicine programs in late stage preclinical development.  Through Dr. Seymour’s leadership at Homology, significant advancements have been made in treatments for rare disorders, with the goal of providing significant benefits for patients with these conditions.